Where the medical guidelines agree, where they disagree, and what's still unknown.
Key Details: What the Experts Say
A 1-minute view of what this section covers. Tap any item to read the full discussion.
The International Menopause Society published 342 evidence-graded recommendations in 2025 — the field has a real consensus process
285 recommendations are research-supported and 57 are good-practice points, developed by 38 authors using GRADE and AGREE II methodology across lifestyle, symptoms, bone, cardiovascular, dementia, and cancer domains.
Hormone therapy is the most effective treatment for hot flashes and night sweats — this is consensus across major international organizations
IMS, FIGO, NAMS, and ICSM agree. Route and formulation matter for safety — transdermal generally carries lower thrombotic risk than oral, with important regimen-specific nuances.
Guidelines genuinely disagree about first-line treatment for perimenopausal mood symptoms
FIGO allows hormone therapy first-line when mood symptoms accompany VMS and sleep disruption. EMAS positions antidepressants as first-line even for mild depression. CANMAT places transdermal estrogens as second-line.
Only 1 of 36 randomized trials on hormone therapy and sexual function enrolled perimenopausal women
A Cochrane review found that none enrolled only women with sexual dysfunction, only 7 studied sexual function as a primary outcome, and 20 of 36 had high risk of bias — a major evidence gap.
Menopause care can feel confusing — some advice conflicts, some research is incomplete, and some patients do not feel heard. But the picture is more complicated than it may seem. There is genuine scientific consensus on many of the questions that matter most to you. There are also real disagreements, and real gaps where the evidence simply does not exist yet.
This section maps what experts agree on, where they diverge, and where the evidence is thin — so you know where to trust the research and where to ask for a clear explanation of what is known, what is uncertain, and how that uncertainty affects your options.
There Is a Real Consensus Process
What Experts Agree On
Hormone therapy is the most effective treatment for in eligible women. This is consensus across IMS, FIGO, NAMS, and ICSM. Route and formulation matter — an generally carries lower thrombotic risk than in guideline framing, though that picture has important regimen-specific nuances covered in the Long-Term Health section.
Estrogen should not be prescribed solely to prevent cardiovascular disease. Despite favorable effects on some risk factors, guidelines are clear: CVD prevention is not an indication for starting hormone therapy.
is indicated only for in postmenopausal women — not for cognition, general well-being, depression, or musculoskeletal health. IMS 2024 is explicit on this boundary.
Genitourinary syndrome of menopause (GSM) is chronic and progressive. It does not resolve on its own. has the strongest evidence base, anchored to an AHRQ systematic review of 68 publications plus a 66-publication evidence map (61). and are first-line pharmacological alternatives (86). Vaginal laser therapy has not shown benefit over sham in controlled trials and is not recommended for routine use.
Premature ovarian insufficiency (POI) requires hormone therapy as primary prevention — for cardiovascular disease, type 2 diabetes, and osteoporosis — not merely symptom relief. Doses are higher than standard menopause treatment. Complementary therapies do not substitute. The Special Populations section covers this in detail.
is specifically effective for insomnia during the menopausal transition (120). SSRIs and SNRIs are core treatments for major depressive disorder when it co-occurs. Newer non-hormonal VMS medications (neurokinin receptor antagonists) are emerging, with trial data covered in the Treatment Options section.
Where Guidelines Diverge
First-line treatment for perimenopausal mood symptoms is genuinely contested. FIGO 2026 allows hormone therapy as first-line when mood symptoms accompany vasomotor symptoms and sleep disruption. EMAS positions antidepressants as first-line even for mild depression. CANMAT places as second-line for perimenopausal depression. The field has not resolved whether hormonally driven mood symptoms and clinical depression are distinct enough to warrant different first-line approaches — or whether that distinction is reliably made in clinical practice.
Breast cancer history changes the decision framework entirely. A 25-member multidisciplinary panel reached 100% agreement that MHT decisions after breast cancer should be individualized — weighing symptom severity, individual relapse risk, and patient preferences — rather than categorically ruled out (88). They also reached 100% agreement that combining systemic estrogen with an aromatase inhibitor is counterproductive. This is why the Breast Cancer & HRT section separates survivor contexts rather than relying on a single blanket statement.
The thrombotic risk picture is more regimen-specific than "transdermal is safer." Transdermal unopposed estrogen shows a favorable signal. But transdermal combined therapy carried a VTE signal in a large Swedish emulated target trial — a finding the broad shorthand does not cover. The Long-Term Health section breaks this down by regimen and endpoint.
Where the Evidence Is Thin
Not all gaps are equal. Some are areas where research is simply early; others are areas where uncertainty can leave patients without clear options.
Bone-health prevention in asymptomatic women. The 2023 IMS/AMS/BMS Practitioner's Toolkit found no clear guidance on when hormone therapy might be indicated to prevent bone loss in women without symptoms — and expanded shared decision-making for this situation (27).
Mental health screening and LMIC populations. No standardized mental health guidelines for menopausal women exist. Most validated screening scales were developed in English-speaking populations. Women in low- and middle-income countries face inconsistent evidence bases and limited tool availability (120, 107).
GSM diagnosis. There is no consensus on the number or type of symptoms needed to diagnose GSM. Urinary symptoms overlap with overactive bladder and other urologic conditions, and sexual pain can stem from pelvic floor dysfunction, lichen sclerosus, or vestibulodynia rather than GSM alone (61, 86).
POI formulation evidence. No randomized controlled trials compare hormone therapy formulations specifically in women with POI. Asian POI data are limited. Optimal dosing across the reproductive age range is unknown (60).
Complementary therapies. A systematic review of 158 studies (114 RCTs) found moderate-certainty evidence only for , certain Chinese herbal medicines, and vitamin D for fracture risk. Most other therapies had low or very low certainty. 54% of included RCTs had high risk of bias, and 72% of the reviews scored critically low on the AMSTAR2 quality tool (109).
Sexual function during perimenopause specifically. A Cochrane review of 36 RCTs (23,299 women) found that only 1 trial evaluated perimenopausal women. None enrolled only women with sexual dysfunction. Only 7 studied sexual function as their primary outcome. 20 of 36 had high risk of bias (22).
Sarcopenia. IMS 2025 flags muscle health during menopause as requiring "urgent attention" — but a systematic review of 43 studies found no consistent evidence that hormone therapy prevents or treats sarcopenia. None of the included studies used modern consensus sarcopenia definitions (68).
Breast cancer risk quantification after hormone therapy. Robust randomized trial evidence to precisely quantify risk and benefit magnitude for women with breast cancer history does not yet exist. The cited expert panel recommends the MENO-ABC trial for patients considering this decision (88).
The Shared Decision-Making Principle
Across all of these areas — consensus, disagreement, and gap — one principle recurs: shared decision-making between you and your doctor, based on your specific situation, is how the field handles the places where evidence is strong but individual risk varies, or where evidence is thin. This is not a hedge. It is the method the guidelines themselves recommend when one-size-fits-all answers do not exist.
Questions to Bring to Your Doctor
"Which guideline framework do you use when making menopause treatment decisions — IMS, NAMS, or something else?"
"For my specific symptoms, is the evidence strong enough for a clear recommendation — or is this an area where we're making a judgment call together?"
"Are there areas where the evidence has changed recently that might affect my treatment plan?"
"I've heard conflicting things about [specific topic]. Can you walk me through what the current research actually says?"
